187 related articles for article (PubMed ID: 37439384)
21. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
22. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Novak AJ; Darce JR; Arendt BK; Harder B; Henderson K; Kindsvogel W; Gross JA; Greipp PR; Jelinek DF
Blood; 2004 Jan; 103(2):689-94. PubMed ID: 14512299
[TBL] [Abstract][Full Text] [Related]
23. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
24. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
26. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow adiposity and multiple myeloma.
Morris EV; Edwards CM
Bone; 2019 Jan; 118():42-46. PubMed ID: 29548987
[TBL] [Abstract][Full Text] [Related]
28. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
29. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
[TBL] [Abstract][Full Text] [Related]
30. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
31. Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient.
Koh Y; Jung WJ; Ahn KS; Yoon SS
Biomed Res Int; 2014; 2014():510408. PubMed ID: 25343143
[TBL] [Abstract][Full Text] [Related]
32. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
33. A murine model of human myeloma bone disease.
Garrett IR; Dallas S; Radl J; Mundy GR
Bone; 1997 Jun; 20(6):515-20. PubMed ID: 9177864
[TBL] [Abstract][Full Text] [Related]
34. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
35. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
36. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
37. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.
Miyakawa Y; Ohnishi Y; Tomisawa M; Monnai M; Kohmura K; Ueyama Y; Ito M; Ikeda Y; Kizaki M; Nakamura M
Biochem Biophys Res Commun; 2004 Jan; 313(2):258-62. PubMed ID: 14684154
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
40. [Advances in Modeling of Multiple Myeloma in Mice].
Gu XY; Tang WJ; Li Y; Zhang L; Zheng YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):512-518. PubMed ID: 37407542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]